References
- Ramirez RA, Chauhan A, Gimenez J, Thomas KEH, Kokodis I, Voros BA. Management of pulmonary neuroendocrine tumors. Rev Endocr Metab Disord. 2017;18(4):433–442. doi:https://doi.org/10.1007/s11154-017-9429-9.
- Nicholson A. ES17.03 Updates in squamous cell carcinoma and neuroendocrine tumors of the lung. J Thorac Oncol. 2021;16(3):S82. doi:https://doi.org/10.1016/j.jtho.2021.01.039.
- Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, WHO Panel, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:https://doi.org/10.1097/JTO.0000000000000630.
- Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. JCO. 2005;23(34):8774–8785. doi:https://doi.org/10.1200/JCO.2005.02.8233.
- Glisson BS, Moran CA. Large-cell neuroendocrine carcinoma: controversies in diagnosis and treatment. J Natl Compr Canc Netw. 2011;9(10):1122–1129. doi:https://doi.org/10.6004/jnccn.2011.0093.
- Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;22(14):3618–3629. doi:https://doi.org/10.1158/1078-0432.CCR-15-2946.
- Miyoshi T, Umemura S, Matsumura Y, Mimaki S, Tada S, Makinoshima H, et al. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res. 2017;23(3):757–765. doi:https://doi.org/10.1158/1078-0432.CCR-16-0355.
- Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJM, PALGA-Group, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24(1):33–42. doi:https://doi.org/10.1158/1078-0432.CCR-17-1921.
- Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, Choi YS, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer. 2012;77(2):365–370. doi:https://doi.org/10.1016/j.lungcan.2012.04.009.
- Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24(6):1548–1552. doi:https://doi.org/10.1093/annonc/mdt009.
- Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013;8(7):980–984. doi:https://doi.org/10.1097/JTO.0b013e31828f6989.
- Christopoulos P, Engel-Riedel W, Grohé C, Kropf-Sanchen C, von Pawel J, Gütz S, et al. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. Ann Oncol. 2017;28(8):1898–1902. doi:https://doi.org/10.1093/annonc/mdx268.
- Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, PALGA group, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J. 2017;49(6):1601838. doi:https://doi.org/10.1183/13993003.01838-2016.
- Aykan NF, Özatlı T. Objective response rate assessment in oncology: current situation and future expectations. World J Clin Oncol. 2020;11(2):53–73. doi:https://doi.org/10.5306/wjco.v11.i2.53.
- Steven I Gutman MP, Grant MD, Basch E, Oliansky DM, Aronson N. Progression-free survival: what does it mean for psychological well-being or quality of life? 290-2007-10058-I. Rockville (MD): AHRQ Publication No. 13-EHC074-EF: Agency for Healthcare Research and Quality; 2013.
- U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for biologics evaluation and research (cber) guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. Rockville (MD); 2007.
- Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, IMpower133 Study Group, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:https://doi.org/10.1056/NEJMoa1809064.
- Derks JL, Leblay N, Lantuejoul S, Dingemans AC, Speel EM, Fernandez-Cuesta L. New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management. J Thorac Oncol. 2018;13(6):752–766. doi:https://doi.org/10.1016/j.jtho.2018.02.002.
- George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9(1):1048. doi:https://doi.org/10.1038/s41467-018-03099-x.
- Baine MK, Rekhtman N. Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis. Transl Lung Cancer Res. 2020;9(3):860–878. doi:https://doi.org/10.21037/tlcr.2020.02.13.
- Lantuejoul S, Fernandez-Cuesta L, Damiola F, Girard N, McLeer A. New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. Transl Lung Cancer Res. 2020;9(5):2233–2244. doi:https://doi.org/10.21037/tlcr-20-269.
- Tokito T, Kenmotsu H, Watanabe R, Ito I, Shukuya T, Ono A, et al. Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens. Int J Clin Oncol. 2014;19(1):63–67. doi:https://doi.org/10.1007/s10147-012-0509-2.
- Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, et al. Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes. Clin Lung Cancer. 2016;17(5):e121–e129. doi:https://doi.org/10.1016/j.cllc.2016.01.003.
- Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer. 2005;49(2):217–223. doi:https://doi.org/10.1016/j.lungcan.2005.01.008.
- Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, et al. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. Clin Cancer Res. 2020;26(4):892–901. doi:https://doi.org/10.1158/1078-0432.CCR-19-0556.
- Komiya T, Ravindra N, Powell E. Role of immunotherapy in stage IV large cell neuroendocrine carcinoma of the lung. Asian Pac J Cancer Prev. 2021;22(2):365–70. doi:https://doi.org/10.31557/APJCP.2021.22.2.365.
- Giaj LM, Mazieres J, Audigier-Valette C, Molinier O, Planchard D, Frappat V, Ferrer L, Toffart A, Moro-Sibilot D. P1.07-012 Efficacy of immune checkpoint inhibitors in large cell neuroendocrine lung cancer: results from a French retrospective cohort. J Thorac Oncol. 2017;12:S702-S3.